首页> 美国卫生研究院文献>International Scholarly Research Notices >Self-Microemulsifying Drug Delivery Systems: An Attractive Strategy for Enhanced Therapeutic Profile
【2h】

Self-Microemulsifying Drug Delivery Systems: An Attractive Strategy for Enhanced Therapeutic Profile

机译:自微乳化药物输送系统:增强治疗效果的有吸引力的策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ease of administration and painless approach made oral route the most preferred. Poor oral bioavailability is pronounced with the majority of recent active ingredients because of dissolution rate limited absorption. Failure to attain intended therapeutic effect of the poor water soluble drugs by this route led to development of novel drug delivery systems which will fulfill therapeutic needs with minimum dose. Although many formulation approaches like solid dispersions, complexation, pH modification, and cocrystals exist, lipid based delivery systems finding increased appliance with the apparent increase in absorption of drug. Among lipid based formulations, self-microemulsifying formulations (droplet size < 100 nm) are evident to improve the oral bioavailability of hydrophobic drugs primarily due to their efficiency in facilitating solubilization and in presenting the hydrophobic drug in solubilized form whereby dissolution process can be circumvented. Various components that are used to formulate these dosage forms like surfactants and lipids contribute to the overall improvement in oral bioavailability via promoting the lymphatic transport; thereby hepatic first pass metabolism can be surmounted. The present paper gives exhaustive information on the formulation design and characterization of SMEDDS along with the probable mechanisms by which the bioavailability can be improved with SMEDDS.
机译:易于给药和无痛方法使口服途径成为最优选的途径。由于溶解速率限制了吸收,大多数最新活性成分的口服生物利用度很差。通过这种途径未能获得水溶性差的药物的预期治疗效果导致了新型药物递送系统的开发,该系统将以最小剂量满足治疗需求。尽管存在许多诸如固体分散体,络合,pH调节和共晶的配制方法,但是基于脂质的递送系统发现了增加的装置,同时药物的吸收也明显增加。在基于脂质的制剂中,自微乳化制剂(液滴尺寸(<100 nm)明显改善了疏水性药物的口服生物利用度,这主要是由于它们促进了增溶作用和呈加溶形式的疏水性药物的效率,从而可以规避溶解过程。用于配制这些剂型的各种成分(例如表面活性剂和脂质)通过促进淋巴运输,有助于口服生物利用度的整体改善;从而可以克服肝脏的首过代谢。本文提供了有关SMEDDS的配方设计和表征的详尽信息,以及通过SMEDDS改善生物利用度的可能机理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号